Long $NSPH for .40's and beyond
NSPH has moderate negative correlation with larger NASX biotech's. BIB charts implying corrective phase coming. NSPH is a beaten down stock with good risk-reward here and I believe Verigene System (FDA cleared) could be game-changer for Nanosphere.
A few excerpts from finance.yahoo.com/news/scripps-study-illustrates-clinical-economic-120000635.html :
"The statistically significant findings included a 25.7 hour reduction in time to targeted therapy (61.1 versus 35.4 hours), a 1.9 day median reduction in length of stay (9.1 versus 7.2 days) and $7,240 reduction in median hospital costs per patient ($17,530 versus $10,290)."
''A majority of health care in the U.S. is provided in community-based hospitals. These study findings demonstrate the profound impact on patient care and hospital costs the Verigene System can deliver to a wide spectrum of health care settings,' said Michael McGarrity, Nanosphere's president and chief executive officer."
A few excerpts from finance.yahoo.com/news/scripps-study-illustrates-clinical-economic-120000635.html :
"The statistically significant findings included a 25.7 hour reduction in time to targeted therapy (61.1 versus 35.4 hours), a 1.9 day median reduction in length of stay (9.1 versus 7.2 days) and $7,240 reduction in median hospital costs per patient ($17,530 versus $10,290)."
''A majority of health care in the U.S. is provided in community-based hospitals. These study findings demonstrate the profound impact on patient care and hospital costs the Verigene System can deliver to a wide spectrum of health care settings,' said Michael McGarrity, Nanosphere's president and chief executive officer."
면책사항
이 정보와 게시물은 TradingView에서 제공하거나 보증하는 금융, 투자, 거래 또는 기타 유형의 조언이나 권고 사항을 의미하거나 구성하지 않습니다. 자세한 내용은 이용 약관을 참고하세요.